Kymera Therapeutics Inc Q3 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Marc Frahm - TD Cowen - Analyst : Thanks for taking my questions. Maybe thinking to the 621 healthy volunteer data. And thanks for the kind of clarity on exactly kind of where the target profile is. But maybe thinking through to the TH2 biomarkers, investors seem to be really trying to comp this to what was seen with dupi as you alluded to. How reliable do you think those changes, this percent changes in IgE and TARC from the healthy volunteer study, almost a decade ago, really are how comparable and how tight of a range do you think you need to get to?

Question: Marc Frahm - TD Cowen - Analyst : Long, but very helpful. Then maybe just more on the model with Bruce, just talk through with the kind of continuing prioritization of the immunology side. Are there kind of any savings of that from the oncology or it's all going to be redeployed into immunology?

Question: Kalpit Patel - B. Riley Securities - Analyst : Yeah. Hey, good morning and thanks for taking the question. Maybe just one on the STAT6 program here. I'm curious if you've made comparisons to dupi, pre-clinically if you've looked at the change in ear thickness and the atopic derm model, the MC930. And as a follow up, I think the 32 milligrams per kilogram showed the most reductions in IgE, so I'm curious what that dose translates into humans? Thank you.

Question: Kalpit Patel - B. Riley Securities - Analyst : Okay. Got it. Thanks for taking the questions.

Question: Alex Sanagasan - Truist Securities - Analyst : This is [Alex Sanagasan] for Kripa. A question on the TYK2 asset. We had some conversations with investors about what they would describe as a slow launch for TYK2, citing some efficacy, good efficacy, and indications like psoriasis and maybe some challenges and others like IBD. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 31, 2024 / 12:30PM, KYMR.OQ - Q3 2024 Kymera Therapeutics Inc Earnings Call Do you think that a degrader could address these issues and provide additional benefit? And when you think about future enrollments for the studies, would you consider enrolling in TYK2 inhibitor experienced patients in the trial as an expanded opportunity? Thanks.

Question: Brad Canino - Stifel - Analyst : Hi, good morning. I know you stated in the prepared remarks that the next steps for STAT6 will be shared after the SAD, MAD results, and hitting that 90% plus degradation safely. But dupilumab replication in TH2 patients is the major question. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 31, 2024 / 12:30PM, KYMR.OQ - Q3 2024 Kymera Therapeutics Inc Earnings Call Is there a particular type of TH2 disease where this test is best to conduct? I guess how much duration of testing is likely needed. And do you need hard clinical endpoints or will biomarkers in patients be sufficient to accelerate mid to late stage development? Thank you.

Question: Brad Canino - Stifel - Analyst : Appreciate it.

Question: Kelly Shi - Jefferies - Analyst : Congrats on the progress, and thank you for taking my questions. I would appreciate your insights on what are the major differentiations of targeting

Question: Kelly Shi - Jefferies - Analyst : Great. Thanks.

Question: Jeff Jones - Oppenheimer & Co. Inc. - Analyst : Good morning guys, and thanks for taking the question. I guess we'll stay on 621 and STAT6. Clearly you guys aren't the only ones targeting STAT6 and your IRAK4 partners to know if he's working with both Recludix and Neurax. Could you comment on the differentiation between a degrader approach here for STAT6 versus the small molecule approach? And maybe any differentiation between your degrader platform and Neurax? Thank you.

Question: Jeff Jones - Oppenheimer & Co. Inc. - Analyst : Appreciate the update guys. Thank you.

Question: Eric Joseph - JPMorgan - Analyst : Hi, good morning. Just picking up on the Phase 1 trial with 621. Could you -- I'm sorry if I missed it, but can you give us a sense of sort of the number of those cohorts and patient numbers that you're evaluating and the SAD, MAD. And whether the read out in the first half would include both SAD and MAD components or maybe a partial read out thereof. And yeah, and the extent of which sort of the prior Phase 1 with the IRAK4 is a useful road map here.

Question: Eric Joseph - JPMorgan - Analyst : Yes. Thanks for that detail. And yes, we were looking for the trial entry, couldn't find it. But anyway, thank you. Follow-up just with the kind of the focus going forward here in I&I, any, I guess we should be anticipating additional targets programs here in that space over the next year or so.

Question: Michael Schmidt - Guggenheim - Analyst : Hey, good morning. Thanks for taking my question. Another one on 621. Nello, so degraders as a modality have obviously been very safe so far. But based on the mechanism and perhaps preclinical data, what are potential on target or perhaps off target AEs that one might expect to see in the study at high 621 doses in the clinic, and what our learnings from STAT6 knockout animal models. Thanks so much. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 31, 2024 / 12:30PM, KYMR.OQ - Q3 2024 Kymera Therapeutics Inc Earnings Call

Question: Michael Schmidt - Guggenheim - Analyst : Great and just a quick follow up. So, in terms of subsequent studies, how do you think about prioritizing potential indications? Would you move into AD first perhaps I know there's a lot of work on STAT6 out there in lung inflammation. So asthma is that top of the list, or how do you how do you plan on prioritizing potential opportunities?

Question: Faisal Khurshid - Leerink Partners - Analyst : Hey guys, thanks for taking the question. I realize this might be premature but wanted to ask anyways. So how are you thinking about partnership opportunities on KT-621? And when do you think the best time for that would be?

Question: Faisal Khurshid - Leerink Partners - Analyst : Great. Thank you.